Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Project Oncology®
Evolving Treatment Strategies in ALK+ Non-Small Cell Lung Cancer
Jorge Nieva, MD
- Jorge Nieva, MD
Comprehensive Molecular Testing in ALK+ Non-Small Cell Lung Cancer
Comprehensive Molecular Testing in ALK+ Non-Small Cell Lung Cancer
Project Oncology®
Comprehensive Molecular Testing in ALK+ Non-Small Cell Lung Cancer
Urs Weber, MD
- Urs Weber, MD
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
Project Oncology®
Beyond ALK Inhibition: Addressing Unmet Needs in Non-Small Cell Lung Cancer
Urs Weber, MD
- Urs Weber, MD
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
Project Oncology®
Building on Progress in ALK+ Non-Small Cell Lung Cancer Treatment
Urs Weber, MD
- Urs Weber, MD
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Project Oncology®
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Steve Jackson, PharmD; Nisha Joseph, MD
- Steve Jackson, PharmD
- Nisha Joseph, MD
NEW EPISODE
De Novo mHSPC: Recognizing the Patients Who Need More
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®
De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Oncology and Hematology
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
- Chan Y. Cheah, MBBS
EHA 2026: Long-Term Zanubrutinib Outcomes
EHA 2026: Long-Term Zanubrutinib Outcomes
Oncology and Hematology
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
- Alessandra Tedeschi, MD

Medical News

Medical News
Limits of AI for Skin Cancer Diagnosis in Real-World Settings
06/25/2026
Read more
Medical News
Robotic Versus Laparoscopic Radical Nephroureterectomy in UTUC
06/25/2026
Read more
Medical News
Meta-Analysis Links Heart Failure Therapies to Better Cardiac Function During Cancer Treatment
06/25/2026
Read more
Medical News
Lorlatinib in Previously Treated Alk-Positive Metastatic Nsclc
06/24/2026
Read more

CME/CE

NEW EPISODE
Molecular Profiling in mHSPC: Informing Treatment Selection
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®
Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Case: Implementing ADT Intensification in mHSPC
Case: Implementing ADT Intensification in mHSPC
MinuteCE®
Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits

Clinical Practice

Patient-Centered Care in ALK+ Non-Small Cell Lung Cancer
Patient-Centered Care in ALK+ Non-Small Cell Lung Cancer
Project Oncology®
Patient-Centered Care in ALK+ Non-Small Cell Lung Cancer
Jorge Nieva, MD
- Jorge Nieva, MD
NEW EPISODE
ADT Intensification: The Evidence You Can’t Afford to Miss
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®
ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Targeting PTEN: Why It Matters
Targeting PTEN: Why It Matters
MinuteCE®
Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Addressing Oncology-Related Infertility Through Collaborative Care
Addressing Oncology-Related Infertility Through Collaborative Care
Clinician's Roundtable
Addressing Oncology-Related Infertility Through Collaborative Care
Irene Su, MD, MSCE
- Irene Su, MD, MSCE

Programs

Side Effect Management in ALK+ Non-Small Cell Lung Cancer Care
Side Effect Management in ALK+ Non-Small Cell Lung Cancer Care
Project Oncology®
Side Effect Management in ALK+ Non-Small Cell Lung Cancer Care
Urs Weber, MD
- Urs Weber, MD
Rising Colorectal Cancer in Young Adults: Implications for Screening
Rising Colorectal Cancer in Young Adults: Implications for Screening
Clinician's Roundtable
Rising Colorectal Cancer in Young Adults: Implications for Screening
Christopher Cann, MD
- Christopher Cann, MD
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Project Oncology®
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Steve Jackson, PharmD; Lyudmila A. Bazhenova, MD
- Steve Jackson, PharmD
- Lyudmila A. Bazhenova, MD
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits